Bristol-Myers Squibb (BMY) Announces Positive Data in ORENCIA Phase III in Patients with RA
Bristol-Myers Squibb Company (NYSE: BMY) announced that new Phase III clinical data show that a weekly subcutaneous injection of an investigational formulation of ORENCIA (abatacept), following a single intravenous (I.V.) loading dose, provided an improvement in disease activity similar to the improvement seen with monthly I.V. administration of ORENCIA in patients with moderate to severe rheumatoid arthritis (RA).
Improvement in disease activity was measured using the ACR20 criteria (a measurement of RA disease state improvement). The ACQUIRE (Abatacept Comparison of Sub(Qu)cutaneous vs. Intravenous in Inadequate Responders to Methotrexate) trial is a multinational study involving 1,457 patients. ORENCIA has the potential to become the first biologic agent to offer physicians and their appropriate RA patients the flexibility to choose either weekly subcutaneous or monthly I.V. administration. The ACQUIRE results will be presented on November 10 at the American College of Rheumatology (ACR) Annual Scientific Meeting, which is being held in Atlanta from November 6 to 11.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Improvement in disease activity was measured using the ACR20 criteria (a measurement of RA disease state improvement). The ACQUIRE (Abatacept Comparison of Sub(Qu)cutaneous vs. Intravenous in Inadequate Responders to Methotrexate) trial is a multinational study involving 1,457 patients. ORENCIA has the potential to become the first biologic agent to offer physicians and their appropriate RA patients the flexibility to choose either weekly subcutaneous or monthly I.V. administration. The ACQUIRE results will be presented on November 10 at the American College of Rheumatology (ACR) Annual Scientific Meeting, which is being held in Atlanta from November 6 to 11.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Apricus Biosciences (APRI) Granted Request for MycoVa Type C Regulatory Guidance from FDA
- Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
